Dr. Rashmika Rushikesh Potdar, MD

Dr. Potdar practices at Reading Hospital in West Reading, Pennsylvania, part of Tower Health.

Dr. Potdar's NPI, 1235578634, was assigned on June 19, 2013. Dr. Potdar holds Pennsylvania license MD467302.

Dr. Potdar's primary practice is Reading Hospital, at 420 S 5th Avenue, West Reading, PA 19611 in Berks County. The practice phone is (610) 988-8000.

Dr. Potdar's primary practice is Reading Hospital in West Reading, Pennsylvania, part of Tower Health. Dr. Potdar is also affiliated with Geisinger Medical Center. The medical group on file is Phoenix Physical Therapy. Dmand AI also links Dr. Potdar to 2 more hospitals and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Potdar practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Potdar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Potdar is licensed in Pennsylvania.

CMS data shows 848 Medicare services from Dr. Potdar across 9 procedure codes in 2024, for 436 Medicare patients. Medicare paid $73,087 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 436 Medicare patients who saw Dr. Potdar in 2024. The largest group is 75 to 84, with 174 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Potdar's median patient age at 67, with 67% women.

In 2024, Dr. Potdar wrote 821 Medicare Part D claims for 196 patients. 87% of them were for generic drugs. CMS names the drug for 666 of them, across 19 drugs with 11 or more claims each, at $498,477 in total drug cost. In 2023, CMS named 506 claims across 17 drugs.

Dr. Potdar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Potdar as offering telehealth.

Dmand AI links 18 papers to Dr. Potdar, published from 2017 to 2023. 2021 was the busiest year, with 6. The most frequent topics are Antineoplastic Agents. Dr. Potdar has published most often in Med Oncol. Dr. Potdar's most frequent co-authors are Gabor Varadi, MD, Sorab Gupta, MD and Andrew Chua Tiu, MD.

CMS Open Payments shows 88 general payments to Dr. Potdar from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 38% of the total. Novartis Pharmaceuticals Corporation paid the most, $2,576.